Schering’s Lotrimin Ultra Only Rx-To-OTC Switch Of 2001
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's Lotrimin Ultra topical antifungal was the first Rx-to-OTC switch drug approved by FDA in 25 months and the only switch in 2001
You may also be interested in...
Novartis Consumer Health Reshuffled, Functional Foods On Sales Block
Novartis is reorganizing its consumer health division by grouping together three businesses - OTC drugs, infant and baby and medical nutrition - and operating animal health and Ciba Vision as separate units, the firm stated during a year-end analysts call Feb. 7
Lotrimin Ultra Antifungal Switch Approved By FDA
Schering-Plough's Lotrimin Ultra will launch nationwide in the first quarter of 2002, marking the third generation of OTC athlete's foot antifungals to bear the Lotrimin name
Third Class Of Drugs Should Not Be “Completely Closed Down” – Ganley
Debate on the merits of a third class of drugs could resurface as FDA considers Rx-to-OTC switch applications of drugs indicated for chronic conditions